XGN stock forecast, quote, news & analysis
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand... Show more
Exagen (XGN) Stock Analysis: Record Test Volume and a Path Toward Breakeven
Key Takeaways
- Exagen shares have been largely range-bound over the past month, trading near $8.53 with little net change from roughly 30 days earlier.
- Second-quarter 2026 revenue reached a record $19.9 million, up 16% year over year, alongside all-time-high test volume and average selling price (ASP).
- Adjusted EBITDA loss narrowed to about $0.1 million, essentially breakeven, prompting the company to raise full-year 2026 revenue guidance to $72–$75 million.
- Growth is driven by expanding adoption of the flagship AVISE CTD test, disciplined revenue-cycle execution, and a growing Pharma Services backlog.
- A myositis diagnostic, the company's first new standalone product since 2020, is targeted for commercialization in early 2027.
- Exagen estimates the U.S. autoimmune testing market at more than $2.2 billion, with the company holding just over 3% share.
- For additional detail, investors can review Exagen's Price Targets, Earnings, and Forecast on dedicated pages.
- Readers can also explore Trending AI Robots to see how automated strategies are trading this and other tickers.
Current Market Snapshot
Exagen Inc. (XGN) has traded in a broad band between roughly $7 and $9 over recent weeks, with the latest available price near $8.53 representing a move of under 1% compared with its closing level about 30 calendar days earlier. This muted short-term action stands in contrast to the company's improving fundamentals, as investors weigh steady execution against an unprofitable bottom line. The stock remains in the small-cap diagnostics space, where sentiment is sensitive to reimbursement developments, test-volume trends, and progress toward profitability.
Exagen (XGN) Business Overview and Competitive Position
Exagen is a provider of autoimmune diagnostics headquartered in San Diego County, California. The company designs, develops, and commercializes testing products under the AVISE brand to help clinicians diagnose, prognose, and monitor complex rheumatic and autoimmune conditions, including systemic lupus erythematosus (SLE) and rheumatoid arthritis. Its flagship product, AVISE CTD, supports the differential diagnosis of connective tissue diseases, while the AVISE Lupus platform uses proprietary cell-bound complement activation products (CB-CAPs) biomarkers to aid earlier, more accurate lupus detection. All testing is performed in Exagen's CLIA-certified, CAP-accredited laboratory.
Exagen's competitive strengths include a differentiated biomarker portfolio, a specialty sales force focused on rheumatologists, and a steadily expanding ordering-clinician base that exceeded 2,800 clinicians in the second quarter of 2026. Investors follow the stock closely because the company is executing a self-funded turnaround centered on higher-quality test volume, improving reimbursement, and a planned cadence of new product launches.
Recent Developments Driving XGN
The most significant recent catalyst was Exagen's second-quarter 2026 report, which showed record revenue of $19.9 million, up 16% year over year. AVISE CTD test volume rose 11% to nearly 39,000 tests, trailing 12-month ASP expanded to $446, and Pharma Services revenue more than doubled. Management raised full-year 2026 revenue guidance to $72–$75 million, citing strength across adoption, ASP, and innovation.
Additional developments have reinforced the clinical story. In June 2026, Exagen announced publication of a systematic review indicating its AVISE Lupus test uniquely identified roughly 25% of SLE patients who would otherwise be missed by conventional markers. The company also continued to build its Pharma Services backlog, which stood at more than $5 million, and advanced a myositis diagnostic toward a launch planned for early 2027. On the analyst front, coverage has included a Buy initiation from Roth Capital, and consensus views the stock favorably with an average rating in the "Strong Buy" range.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies spanning hundreds of AI bots that monitor thousands of tickers. Rather than listing every available bot, the section surfaces top-performing and most relevant strategies based on recent results. These bots vary in trading style, timeframe, and performance metrics, giving users a way to compare different approaches to the same market conditions. For investors interested in how algorithmic systems are positioning across equities, the page offers a neutral, data-driven starting point to review active strategies and evaluate their track records.
2026 Outlook and What Investors Should Watch
Heading into the remainder of 2026, the key themes for Exagen are execution against its raised revenue guidance, continued ASP improvement through revenue-cycle management, and progress toward sustainable positive cash flow. Investors will likely monitor quarterly test-volume growth relative to the roughly 5% annual growth of the broader autoimmune testing market, as well as the productivity of the expanded sales force.
The myositis product launch targeted for early 2027 represents the most significant near-term innovation milestone, and updates on its timing and clinical reception could shape sentiment. Reimbursement remains a central variable, including the status of a potential Medicare Local Coverage Determination and ongoing commercial payer engagement. As with any small-cap diagnostics company carrying a history of net losses, cash runway, collection timing, and the pace of margin improvement are important factors to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XGN in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026
The 10-day moving average for XGN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for XGN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 159 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 45 cases where XGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In 80 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.522) is normal, around the industry mean (67.298). P/E Ratio (-7.085) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. XGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
Industry MedicalSpecialties